| Johnson & Johnson18 programs in shared conditions | 10 · 5 with both in phase 3Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Multiple Myeloma +7 | lazertinib, amivantamab, nipocalimab +4 | - Qilu Pharmaceutical Co., Ltd.’s QLS4131 in a combination vs daratumumab (most trials: Johnson & Johnson) (Multiple Myeloma, NCT07933432)
- Qilu Pharmaceutical Co., Ltd.’s QL2109 in a combination vs daratumumab (most trials: Johnson & Johnson) (Multiple Myeloma, NCT07400744)
- Qilu Pharmaceutical Co., Ltd.’s QL2109 in a combination vs Daratumumab and Hyaluronidase-fihj (most trials: Johnson & Johnson) (Multiple Myeloma, NCT06742138)
- and 1 more
|
| Merck & Co., Inc21 programs in shared conditions | 17 · 5 with both in phase 3Carcinoma, Non-Small-Cell Lung, Hyperlipoproteinemia Type II, Prostatic Neoplasms +14 | sacituzumab tirumotecan, patritumab deruxtecan, intismeran autogene +6 | - Qilu Pharmaceutical Co., Ltd.’s QL2107 vs pembrolizumab (US & EU rights: Merck & Co., Inc) (Carcinoma, Non-Small-Cell Lung, NCT07162883)
- Qilu Pharmaceutical Co., Ltd.’s apripitant and palonosetron injectable emulsion vs Aprepitant (EU rights: Merck & Co., Inc) (Vomiting, NCT07817004)
|
| Amgen12 programs in shared conditions | 9 · 4 with both in phase 3Diabetes Mellitus, Type 2, Macular Degeneration, Prostatic Neoplasms +6 | maridebart cafraglutide, aflibercept, xaluritamig +1 | - Qilu Pharmaceutical Co., Ltd.’s daprodustat vs Darbepoetin alfa (US & EU rights: Amgen) (Anemia, NCT07300111)
- Qilu Pharmaceutical Co., Ltd.’s QL1203 added to Panitumumab (US & EU rights: Amgen) (Colorectal Neoplasms, NCT07829588)
|
| Pfizer28 programs in shared conditions | 16 · 8 with both in phase 3Asthma, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms +13 | tilrekimig, atirmociclib, prifetrastat +7 | - Qilu Pharmaceutical Co., Ltd.’s pralurbactam in a combination vs avibactam, ceftazidime drug combination (most trials: Pfizer) (Pneumonia, Bacterial, NCT07327619)
|
| Sanofi13 programs in shared conditions | 9 · 2 with both in phase 3Dermatitis, Atopic, Purpura, Thrombocytopenic, Idiopathic, Multiple Sclerosis +6 | Dupilumab coformulated with berahyaluronidase alfa, frexalimab, Cholestyramine Resin +1 | - Qilu Pharmaceutical Co., Ltd.’s QL2108 in a combination vs dupilumab (EU rights: Sanofi) (Dermatitis, Atopic, NCT06884891)
|